Illumina Inc. Common Stock (ILMN)

FairStock Score: 42/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the close on 2026-10-13, Illumina traded at $271.18. FairStock calculates a P/E of 50.50, P/B of 14.42, FCF yield of 2.4%, and a Graham Number of $46.13, so the price is far above a conservative asset-based value. The business sells sequencing and array instruments and consumables. It has filed fiscal 2025 revenue of $4.3B, net income of $850M, and diluted EPS of $5.45, after fiscal 2024 revenue of $4.4B but a net loss of $1.2B and diluted EPS of -$7.69. In fiscal Q2 2026, the quarter ended 2026-06-28, revenue was $1.2B, net income $207M, and diluted EPS $1.35. In fiscal Q1 2026, the quarter ended 2026-03-29, revenue was $1.1B, net income $134M, and diluted EPS $0.87. That is a real turnaround, and FairStock labels it a TURNAROUND because it returned to profit after losses within the last three years. The returns are mixed: ROE is 32.34%, but ROCE is 8.67%. Debt-to-equity is 0.89, Altman Z is 6.76, and Piotroski is 5/9. Free cash flow is positive at $967M, but the FCF yield is only 2.4%, so the price already assumes much better days. Fiscal 2025 revenue was slightly below fiscal 2024, which makes the growth story less compelling. I want a margin of safety and evidence that this recovery is durable. At this price, the numbers do not offer one; they ask me to trust the turnaround.

In plain English: Illumina sells machines and chemical kits used to read DNA. The business has swung back to profit after losses, and it makes a high return on shareholders' money, but sales are not growing quickly and the share price is much higher than its reported earnings and net assets would suggest is cheap. At the recent close, the stock looks expensive rather than cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-28) · fiscal Q1 2026 10-Q (period ended 2026-03-29) · fiscal Q4 2025 10-Q (period ended 2025-12-28) · fiscal Q3 2025 10-Q (period ended 2025-09-28) · FY2025 10-K (period ended 2025-12-28) · FY2024 10-K (period ended 2024-12-29) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer